CBC in collaboration with Business Weekly
Cambridge Biomedical Campus and Business Weekly have forged an alliance to promote the venture to potential relocators and collaborators internationally.
With the recent granting of planning permission for an additional 70 acres, the current occupiers of the Cambridge Biomedical Campus – in partnership with the Campus development team – are inviting organisations involved in innovative healthcare-related research, education or patient care to join them on the rapidly-expanding Campus.
Cambridge University Hospitals NHS Foundation Trust, the Cancer Research UK Cambridge Research Institute, the Hutchison/MRC Research Centre, the Medical Research Council Laboratory of Molecular Biology and multiple departments of the University of Cambridge are open to working alongside organisations that can add value to the world-class research, education and clinical practice that is already taking place on the site.
Jeanette Walker, the Project Director acting for Campus developers Liberty Property Trust and Countryside Properties, said she “jumped at the chance to work with Business Weekly to promote the unique assets of the Campus to potential occupiers.”
“This is arguably the most exciting development to take place in Cambridge in recent times,” said Walker. “For the first time, we now have the opportunity to co-locate academics, businesses and clinicians on a single site.
“By creating an environment that facilitates collaboration amongst the occupiers on the campus, we are building a community of like-minded, inter-dependent experts working across disciplines who all share the common goal of improving patient outcomes and patient care.”
Anyone arriving in Cambridge by road or rail will see that the expansion of the Campus is already well underway. The new road off the M11 motorway gives fast and easy access to the site, and in 2011 rail passengers will be able to travel to and from the Campus via the train station on the Cambridgeshire Guided Busway – due to be operational in 2011.
Major new construction projects include the Medical Research Council’s 270,000 square foot Laboratory of Molecular Biology, which is due for completion in 2011; the extension to the Rosie Hospital which is forecast to be completed in July 2012; and the re-location of Papworth Hospital to the Campus in 2015.
The expanded site also includes plans for a new conference centre, hotel and private hospital as well as generous open spaces, landscaped boulevards, cycleways and up to 4,000 new homes adjacent to a 120-acre country park.
So which companies might benefit most from locating on the Cambridge Biomedical Campus?
Walker says: “First of all the Campus is proving to be of particular interest to research-led organisations that might benefit from the clinical expertise and resources within Cambridge University Hospital’s NHS Foundation Trust (Addenbrooke’s and the Rosie Maternity Hospital) as well as Papworth Hospital.
“Given the quality of drug and device-related research and clinical development taking place across the Campus, perhaps it is not surprising that companies interested in stratified medicine see a particular advantage in locating alongside the experts who can help them discover and test medicines for sub-groups of patients.
“The same is true for experimental medicine where companies require access to clinicians who, because of their unique specialist knowledge of a particular disease and patient group, are able to add significant value to a first-in-man study.
“For companies involved in the development of innovative medical devices and diagnostics, the opportunity to collaborate routinely with clinical end-users from an early stage on a face-to-face basis rather than remotely is invaluable, and with the urgent need for healthcare providers to reduce costs whilst improving patient care and treatment outcomes, there is growing interest in technologies that enable the safe and accurate monitoring of patients in the home - another area where Cambridge has world-class expertise.
“In the field of regenerative medicine, the Campus is continually expanding its capabilities in the research and discovery of cell-based therapies and the platform technologies required to enable this area of research and clinical application to progress further.” • These are just some of the areas of medical research and clinical practice where the Cambridge Biomedical Campus has extensive expertise and experience.
If you would like to know more about specific opportunities for your organisation, then please email Jeanette Walker at jeanette [at] cambridge-biomedical.com or visit www.cambridge-biomedical.com